GlassScriptPhysician profile
Koree A Ramsey
NPI 1831620434
$5,243.73
in general payments reported to CMS, 2019-2025
26 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,652 · 2022: $1,695 · 2023: $1,394 · 2024: $290 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,879 · Education: $18.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.75 |
| Education | $18.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,804.97 | 2021-2024 | Trulance, Xifaxan, Plenvu |
| Abbvie INC. | $1,470.96 | 2021-2025 | |
| Gilead Sciences, INC. | $247.68 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $244.74 | 2021-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $204.89 | 2021-2023 | Linzess |
| Qol Medical, LLC | $202.93 | 2021-2024 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $165.46 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.95 | 2023 | |
| Medtronic, INC. | $124.95 | 2023-2025 | Interstim |
| Janssen Biotech, INC. | $124.94 | 2021 | |
| Procept Biorobotics Corporation | $80.34 | 2025 | |
| Celgene Corporation | $77.24 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $66.58 | 2022-2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $47.08 | 2021-2023 | Gattex |
| Lilly USA, LLC | $34.54 | 2024 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.64 | 2021-2022 | |
| Ardelyx, INC. | $30.82 | 2022 | |
| Pfizer INC. | $30.72 | 2024 | |
| Celltrion USA INC. | $18.59 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $18.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.32 | 2023 | Cyltezo |
| Phathom Pharmaceuticals, INC. | $16.48 | 2024 | Voquezna |
| Vivus LLC | $15.73 | 2022 | |
| Genzyme Corporation | $14.66 | 2023 | |
| Merck Sharp & Dohme LLC | $14.55 | 2021 | |
| Pharmacosmos Therapeutics INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Koree Ramsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.